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Central nervous system (CNS) injuries, caused by cerebrovascular pathologies or mechanical contusions (e.g., traumatic brain
injury, TBI) comprise a diverse group of disorders that share the activation of the integrated stress response (ISR). This pathway
is an innate protective mechanism, with encouraging potential as therapeutic target for CNS injury repair. In this review, we will
focus on the progress in understanding the role of the ISR and we will discuss the effects of various small molecules that target the
ISR on different animal models of CNS injury.
1. Introduction
CNS injuries are a diverse group of disorders that include
spinal cord injury (SCI), traumatic brain injury (TBI), and
stroke. Although different in etiology, CNS injuries trigger
shared processes such as disruption of the blood-brain barrier
(BBB) [1, 2] or the blood-spinal cord barrier (BSCB) [3] that
facilitate the extravasation of blood substances and cells into
the CNS parenchyma and vice versa, excitotoxicity [4–6], and
hypoxia/ischemia [5, 7], increase the inflammatory response
activated after injury [5, 7, 8], and spread the initial cell death
due to the injury to other CNS areas, with added detrimental
effects.
This acute neuroinflammatory response causes the acti-
vation of glial cells (mainly astrocytes and microglia) that
counterbalance the changes in tissue homeostasis [9, 10].
Glial cells show enhanced migration into the injured site
[11, 12] and release inflammatory mediators including pro-
and anti-inflammatory cytokines and chemokines [9, 10].
The proinflammatory mediators induce the activation and
recruitment of leukocytes to the inflammation site in the
CNS parenchyma [10, 13]. Activated microglia (CNS resident
macrophages [14]), as well as infiltrating neutrophils [15]
and monocytes [16], phagocyte debris from damaged tissue
and dead cells. Activated astrocytes and mesenchymal cells
(meningeal fibroblasts [17], perivascular fibroblasts [18], and
pericytes [19])migrate to the injury site and attempt to restore
the disrupted BBB or BSCB, secreting extracellular matrix
proteins that induce a new glia limitans, called glial scar [17,
20]. Both phagocytosis of dead cells and glial scar formation
attempt to reduce inflammation and restore tissue homeosta-
sis [21, 22]. However, both processes might have detrimental
effects. Activated microglia/macrophages may phagocyte liv-
ing cells increasing tissue loss [23] and the glial scar is one of
the main obstacles to axonal regeneration after injury [24]. If
these processes cannot restore homeostasis, the inflammatory
response is maintained long after injury.This state of chronic
neuroinflammation increases further the loss of white and
greymatter that characterizesmanyCNSpathologies [25, 26].
2. Integrated Stress Response in CNS Injury
CNS injury can cause oxygen-glucose deprivation, amino
acid deprivation, glutamate excitotoxicity, oxidative stress,
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Figure 1:The integrated stress response is sensitive to numerous stimuli activated after CNS injury. A diverse group of kinases such as GCN2,
HRI, PERK, andPKR induce the phosphorylation of eIF2𝛼 in response to various stimuli resulting in translational attenuation to overcome the
accumulation ofmisfolded or unfolded proteins in the ER and retrieve proteostasis. Phosphorylated eIF2𝛼 (eIF2𝛼-P) enhances the translation
of the transcription factor ATF4 that induces the transcription of prosurvival genes as well as the transcription factor CHOP. Both ATF4
and CHOP cause upregulation of GADD34 expression, which forms a complex with PP1, inducing the dephosphorylation of eIF2𝛼-P and
hence retrieving translation. When protein homeostasis is not restored (indicating cellular damage), CHOP increases the transcription of
proapoptotic genes, inducing cell death. ATF4, activating transcription factor 4; CHOP,C/EBPhomolog protein; eIF2𝛼, eukaryotic translation
initiation factor 2𝛼; GADD34, growth arrest andDNA-damage inducible 34; GCN2, general control nonderepressible 2; HRI, haem-regulated
inhibitor kinase; P, inorganic phosphate; PERK, protein kinase RNA-like endoplasmic reticulumkinase; PKR, double-strandedRNA-activated
protein kinase; PP1, protein phosphatase 1.
and the release of cytokines. These may affect protein
synthesis at the endoplasmic reticulum (ER), inducing the
accumulation of misfolded or unfolded proteins therein
[27–30] (Figure 1). The integrated stress response (ISR) is
activated as a cytoprotective mechanism [31], to maintain
cellular protein-folding homeostasis (also known as pro-
teostasis) [32]. A diverse group of kinases (Figure 1) act as
sensors for different stressors activating the ISR, through
the phosphorylation of the alpha subunit of the eukaryotic
translation initiation factor 2 (eIF2𝛼 to eIF2 𝛼-P) on Serine
51 [32]. Phosphorylated eIF2𝛼 binds to eukaryotic translation
initiation factor 2B (eIF2B). This inhibits its activity and
attenuates protein translation while inducing the translation
of activating transcription factor 4 (ATF4, also known as
CREB2) and other selected genes [30]. ATF4 upregulates the
expression of chaperones (e.g., Bip, also known as GRP78
[33, 34]) that help to reduce protein accumulation in the
ER. It also promotes the expression of prosurvival factors
involved in amino acid metabolism and oxidative stress
resistance [30, 35]. Moreover, ATF4 increases the expression
of transcription factor CHOP (C/EBP homologous protein,
also known as DDIT3, DNA-damage-inducible transcript 3).
BothATF4 andCHOPupregulate the expression ofGADD34
(growth arrest and DNA-damage inducible 34; also known as
protein phosphatase 1 regulatory subunit 15A or PPP1R15A).
GADD34 is a regulatory cofactor of the catalytic subunit of
protein phosphatase 1 (PP1) that directs the dephosphory-
lation of eIF2𝛼 restoring protein synthesis [36]. Should the
restoration of proteostasis fail, the transcription factor CHOP
would cause an increase in the expression of genes involved
in apoptosis, executing the damaged cell [37].
In addition to the stress-inducible GADD34-PP1 com-
plex, CReP (constitutive repressor of eIF2𝛼 phosphorylation,
also known as PPP1R15B) forms a complex with PP1 that
constitutively dephosphorylates eIF2𝛼 [38].
3. CNS Injury Therapeutics Based on
the Integrated Stress Response
CNS injury causes the loss of white and grey matter with
detrimental effects [25, 26]. After the initial cell death and

























Figure 2: Pharmacological regulation of the integrated stress response (ISR).The translation initiation factor eIF2𝛼 is phosphorylated (eIF2𝛼-P)
by a diverse group of kinases. Phosphorylated eIF2𝛼 represses eIF2B inducing translation attenuation as well as activation of a pathway that
induces GADD34 forming a complex with PP1c (GADD34:PP1c). This stress-activated complex induces the desphosphorylation of eIF2𝛼-P
to restore proteostasis. A constitutively activated complex (CReP:PP1c) dephosphorylates eIF2𝛼-P under basal conditions. Salubrinal inhibits
indirectly the activity of both GADD34:PP1c and CReP:PP1c complexes through an unknown target (X). However, Guanabenz and Sephin1
only inhibit the activity of GADD34:PP1c complex. ISRIB overcomes the attenuation of translation induced by eIF2𝛼-P, activating eIF2B
downstream of eIF2𝛼. ADP, adenosine diphosphate; ATP, adenosine triphosphate; CReP, constitutive repressor of eIF2𝛼 phosphorylation;
eIF2𝛼, eukaryotic translation initiation factor 2𝛼; eIF2𝛼B, eukaryotic translation initiation factor 2B; GADD34, growth arrest and DNA-
damage inducible 34; ISRIB, integrated stress response inhibitor; P, inorganic phosphate; PP1c, protein phosphatase 1 catalytic subunit.
tissue destruction caused by the injury, numerous mecha-
nisms are activated spreading both tissue damage and cell
death (like excitotoxicity [4–6], hypoxia/ischemia [5, 7, 8],
and so forth). CNS injuries enhance the ISR pathway as
a cytoprotective mechanism [27, 39], suggesting that the
ISR might be a therapeutic target for CNS injuries. Several
small molecules, such as salubrinal [40], guanabenz [41], and
Sephin1 [42], that enhance ISR have shown cytoprotective
effects.
3.1. Salubrinal. Salubrinal is a small molecule discovered in
a high-throughput screening of compounds with cytoprotec-
tive effect on ER stress-induced cell death [40]. Although the
target for salubrinal is unknown, it maintains eIF2𝛼 highly
phosphorylated, reducing protein synthesis at the ER [40].
Salubrinal inhibits the activity of both CReP-PP1 constitutive
complex and GADD34-PP1 stress-inducible complex (Fig-
ure 2).
Salubrinal has neuroprotective effects in animal models
of CNS injury, such as a rat brain excitotoxicity [43], cere-
bral ischemia/reperfusion [44, 45], and chronic intermittent
hypoxia [46]. It is neuroprotective also in mouse models of
sleep apnea [47], traumatic brain injury [48, 49], and cortical
stab injury [50]. Moreover, salubrinal protects oligoden-
drocytes, reducing demyelination and improving functional
recovery after spinal cord injury [51]. The prosurvival effects
of salubrinal after CNS injury are mediated by decreasing
the ER stress response [43, 45, 48–50]. Limiting energy
consumption is achieved under pathological conditions by
diminishing ER protein overload [52].
Recent evidence suggests that salubrinal treatment may
trigger additional cytoprotective pathways by upregulating
the expression of platelet-derived growth factor subunit B
(PDGF-B) [53–56] in neurons close to the injury [50]. After
a cortical stab injury, salubrinal also helps in restoring the
integrity of the blood-brain barrier (BBB) by inducing an
increase of fibronectin expression and a reduction of the
activation ofmicroglia/macrophages [50]. A rapid restoration
of the BBB integrity following injury is essential to restore
homeostasis [57]. Should this process be delayed or impeded,
blood substances and leukocytes would continue diffusing
into the CNS, triggering an additional inflammatory process.
This would extend the initial injury, strengthening the so-
called secondary neuronal loss, with increased detrimen-
tal effects [58]. PDGF-B is a mitogen for pericytes and
mesenchymal cells [59], inducing both proliferation and
production of fibronectin [60]. The release of PDGF-B in the
proximity of the lesion site might help to close the injury,
accelerating BBB integrity restoration [50]. Moreover, in a
rat model of global cerebral ischemia, salubrinal reduced the
levels of matrix metalloprotease 9 (MMP-9), as well as of the
injury-induced cell adhesionmolecules ICAM-1 andVCAM-
1 [46]. MMP-9 is a typical marker of BBB impairment [61, 62]
and both ICAM-1 and VCAM-1 are involved in leukocyte
migration into the injured CNS [63]. In conclusion, these
results support the restorative effect of salubrinal treatment
on BBB integrity after injury [50, 64]. The reduction of both
microglia activation and bloodmonocyte infiltration into the
injury site may diminish inflammation, reducing neuronal
death and tissue loss after injury [50, 64].
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Salubrinalmay show additional neuroprotective and anti-
inflammatory effects by inhibiting the transcription factor
NF𝜅B pathway [65, 66]. Indeed, salubrinal treatment reduced
both neuronal cell death and microglia activation by 𝛽-
amyloid (A𝛽) [65] inhibiting the NF𝜅B pathway.The authors
propose that these effects are mediated by the inhibition
of IkB kinase (IKK) activation, consequently reducing the
degradation of the NF𝜅B repressor IkB [65]. Another article
reported that both salubrinal and guanabenz selectively
reduce TNF𝛼 but not IL-1𝛽-induced activation of NF𝜅B [66].
This work concluded that the effect occurred upstream of
transforming growth factor/beta-activated kinase 1 (TAK1)
and was independent of eIF2𝛼 [66]. These results suggest
that both salubrinal and guanabenz may regulate also the
phosphorylation of other targets [67].
Following severe CNS injuries, glial cells (mainly astro-
cytes) and mesenchymal cells (fibroblasts and pericytes)
attempt to restore the disrupted BBB, by secreting extra-
cellular matrix proteins and forming a new glia limitans,
called the glial scar [17]. Although glial scar formation has
some beneficial effects [68], it is also one of the main
obstacles to axonal regeneration after injury [24]. The major
axon regenerative growth inhibitors in the glial scar are
the chondroitin sulfate proteoglycans (CSPGs) [69]. The
neuritogenic effects shown by salubrinal in vitro are due to
the inhibition of the expression in glial cells of CSPGs and
other profibrotic proteins, such as CTGF [70]. In addition
to the effect on protein translation, salubrinal reduced the
mRNAs for CSPGs and CTGF [52]. These processes may
work together to reduce protein overload in the ER, speed up
proteostasis, and increase cell survival after CNS injury.
These results suggest that salubrinal could be a good can-
didate for pharmacological therapy of CNS injuries. Detri-
mental effects of salubrinal treatment have been reported
in pancreatic beta cells exposed to fatty acids [71] and in
the neuroprotection induced by preconditioning, in a rodent
model of permanent ischemia [72]. Since the mechanism
of action of salubrinal is unknown, these adverse effects
might be due to inhibition by salubrinal treatment of both
constitutive and stress-induced phosphorylation of eIF2𝛼
[73], or an off-target effect.
3.2. Guanabenz and Sephin1. Guanabenz is an agonist of
the 𝛼2-adrenergic receptor and it is a prescription drug
to treat hypertension [74]. In addition, guanabenz selec-
tively inhibits stress-induced dephosphorylation of eIF2𝛼
by the GADD34:PP1 complex, without affecting the activ-
ity of the constitutively activated CReP:PP1 complex (Fig-
ure 2) [41]. Guanabenz showed beneficial effects in a rodent
model of multiple sclerosis, suggesting that the inhibition of
GADD34:PP1 complex alone was enough to improve mouse
recovery [75]. In particular, guanabenz was cytoprotective
for oligodendrocytes and reduced demyelination [75]. These
positive results have led to a phase I clinical trial to determine
the safe dose of guanabenz formultiple sclerosis patients [73].
In contrast to multiple sclerosis, guanabenz treatment in
rodent models of CNS injuries showed contradictory effects.
Thus, it was cytoprotective for oligodendrocyte precursor
cells (OPC) in vitro, but it did not enhance functional
recovery in a mouse model of SCI [76]. In a rat model of TBI,
guanabenz was neuroprotective, reduced cortical contusion,
and decreased hipocampal cell damage, attenuating motor,
learning, and memory deficits after TBI [77]. However, the
dose of guanabenz in TBI experiments was five times higher
(5mg/Kg) than in SCI experiments (1mg/Kg). In mice,
a dose of guanabenz in that range (1–5mg/Kg) has side
effects manifested by a dose-dependent decrease in rotarod
performances [42].These side effects may be due to the effect
of the drug on adrenergic receptors, lowering mice blood
pressure. TBImice treatedwith the FDA-approved dose range
(0.5mg/Kg) had beneficial effects, but not all the benefits
observed with the higher dose [77]. Guanabenz is used to
lower blood pressure in patients with hypertension. A high
dose of guanabenz has side effects, including drowsiness
and coma [78]. These results hamper the possible use of
guanabenz for treatment of CNS injuries.
Sephin1 is a guanabenz derivative with selective
inhibitory effect on stress-induced dephosphorylation of
eIF2𝛼 by the GADD34:PP1 complex (Figure 2), without
𝛼2-adrenergic activity [42]. Sephin1 showed beneficial
effects on animal models of two protein-misfolding diseases,
Charcot-Marie-tooth 1B (CMT1B) and Amyotrophic lateral
sclerosis (ALS), without any side effect in chronic treatments
[42]. In particular, Sephin1 treatment (1–5mg/Kg) did not
decrease mice performance in rotarod, or in theMorris water
maze, that tests spatial learning [42]. In fact, mice treated
with Sephin1 prevented motor deficits in untreated mice of
MPZmutant (a mouse model of CMT1B) and SOD1mutant (a
mouse model of ALS).
It is unknown whether Sephin1 treatment has beneficial
effects on CNS injuries. The desirable properties of Sephin1,
such as specificity for stress-induced complex and the
reduced 𝛼2-adrenergic activity, deserve a study to determine
its therapeutic potential for CNS injuries.
4. Conclusions
The integrated stress response (ISR) is a cytoprotectivemech-
anism induced in CNS injuries. The enhancement of ISR
pathway by the small molecule salubrinal is neuroprotective
and neuritogenic and helps to restore BBB integrity after
injury. Anew generation of smallmolecules that enhances the
ISR pathway, such as Sephin1, is currently under investigation
to determine their potential for the treatment of CNS injuries.
Preliminary results indicate that the enhancement of the ISR
pathway is a promising therapeutic target for CNS injuries.
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